Incyte Corp (INCY)
84.52
+1.40 +1.68%
NASDAQ
Aug 19, 20:00
Delayed 2m
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 2.006B |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | 1.41 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | 305.87M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 94.45% |
| Profit Margin (Quarterly) | 19.87% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | Upgrade |
| Price and Valuation | |
| Market Cap | 18.18B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | 9.128 |
| PE Ratio (TTM) | 59.94 |
| Price to Book Value | 8.089 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | Upgrade |
| Free Cash Flow (Quarterly) | 105.67M |
| Return on Equity (TTM) | Upgrade |
View All INCY News
News
-
WireHeadlineTime (ET)
-
Yahoo08/19 10:24
-
SA Breaking News08/16 12:36
-
SA Breaking News08/16 10:17
-
Yahoo08/14 08:53
-
Yahoo08/13 12:15
-
MT Newswires08/12 12:06
-
Globe Newswire08/12 06:30
-
Yahoo08/06 10:00
-
Yahoo08/03 01:15
-
MT Newswires07/31 13:23
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 10/30/2019 08:00 EDT | Misc | Incyte Corp Third Quarter Earnings Conference Call in 2019 |
| 10/30/2019 | Earnings | Incyte Corp Third Quarter Earnings in 2019 Release |
| 07/30/2019 08:00 EDT | Misc | Incyte Corp Second Quarter Earnings Conference Call in 2019 |
| 07/30/2019 | Earnings | Incyte Corp Second Quarter Earnings in 2019 Release |
| 04/30/2019 08:00 EDT | Misc | Incyte Corp First Quarter Earnings Conference Call in 2019 |
| 04/30/2019 | Earnings | Incyte Corp First Quarter Earnings in 2019 Release |
| 04/26/2019 13:00 EDT | Misc | Incyte Corp Annual General Meeting in 2018 |
| 02/14/2019 08:00 EST | Misc | Incyte Corp Fourth Quarter Earnings Conference Call in 2018 |
| 02/14/2019 | Earnings | Incyte Corp Fourth Quarter Earnings in 2018 Release |
| 02/14/2019 | Misc | Incyte Corp Annual Report in 2018 |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: http://www.incyte.com
- Investor Relations URL: http://www.incyte.com/ir/investor-overview.aspx
- HQ State/Province: Delaware
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Mid Cap/Growth
- Next Earnings Release: Oct. 30, 2019
- Last Earnings Release: Jul. 30, 2019
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant, which Eli Lilly licenses, and oncology drug Iclusig for chronic myeloid leukemia. Incyte's pipeline includes a broad array of oncology and autoimmune programs, including next-generation JAK inhibitor itacitinib.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 84.52 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| PBE | Invesco Dynamic Biotech & Genome ETF | 5.31% |
| BBH | VanEck Vectors Biotech ETF | 4.80% |
| FBT | First Trust NYSE Arca Biotech ETF | 3.54% |
| IBB | iShares Nasdaq Biotechnology ETF | 2.48% |
| VGHCX | Vanguard Health Care Inv | 2.04% |
| SCGVX | Sands Capital Global Growth Inv | 1.94% |
| FGSCX | Federated MDT Mid Cap Growth C | 1.90% |
| RYH | Invesco S&P 500® Equal Wt Hlth Care ETF | 1.73% |
| XBI | SPDR® S&P Biotech ETF | 1.54% |
| FBIOX | Fidelity® Select Biotechnology | 1.42% |
| ATL1735 | Renaissance Global Health Care Class O | 1.40% |
| NMECX | Nuveen Equity Market Neutral C | 1.05% |
Excel Add-In Codes
- Name: =YCI("INCY","name")
- Description: =YCI("INCY","description")
- Sector: =YCI("INCY","sector")
- Industry: =YCI("INCY","industry")
- Est. Current Fiscal Year End: =YCI("INCY","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- INCY Tweets Stocktwits
Advertisement
